Drug-Drug Interaction Study Between Quinine Sulfate and Rosiglitazone
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
Rosiglitazone is predominantly metabolized by cytochrome P450 (CYP) 2C8. Quinine sulfate is
an inhibitor of CYP 2C8. This study will evaluate the effect of multiple doses of quinine
sulfate at steady-state on the pharmacokinetics of single-dose rosiglitazone in healthy adult
subjects.